Quoin Pharmaceuticals Ltd ADR Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.33 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $4.72Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $9.5M Enterprise Value $7.8M Shares Outstanding 2M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Quoin Pharmaceuticals is a late clinical-stage specialty biopharmaceutical company focused on rare and orphan diseases, primarily targeting Netherton Syndrome with its lead asset QRX003. The company has recently streamlined its pipeline by discontinuing QRX004 and QRX007 to focus resources on QRX003 and its topical rapamycin program (QRX009). With key regulatory milestones achieved—including FDA Fast Track designation and Japanese MHLW Orphan Drug Designation—the upcoming Phase 3 topline data in H2 2026 represents a major near-term catalyst. While the company remains pre-revenue and faces ongoing dilution risks, its current cash position of $14 million provides a runway into 2027, making it an attractive high-risk, high-reward play for biotech investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$12.00 Mean target$21.40 High · most bullish analyst$35.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.5020% QRX003 Phase 3 trials fail to meet primary efficacy endpoints or reveal adverse safety signals, halting the development program. The company is forced to rely on its early-stage QRX009 program, leading to severe capital constraints, massive shareholder dilution, or going-concern issues. Base CaseCentral scenario $30.0055% QRX003 Phase 3 trials meet primary endpoints with acceptable safety profiles. The company completes enrollment by the end of 2026 and prepares for an NDA submission in 2027. Additional capital is raised through disciplined warrant exercises or modest equity offerings, maintaining a stable cash runway. Bull CaseUpside scenario $40.0025% QRX003 Phase 3 trials yield highly positive topline data in H2 2026, showing superior efficacy and safety. The FDA accepts a single Phase 3 trial for NDA submission, leading to accelerated approval and commercial launch by late 2027. Strategic commercial partnerships in Europe and Japan trigger upfront milestone payments, eliminating near-term dilution. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |